Search

Your search keyword '"Vogelgsang, J."' showing total 70 results

Search Constraints

Start Over You searched for: Author "Vogelgsang, J." Remove constraint Author: "Vogelgsang, J."
70 results on '"Vogelgsang, J."'

Search Results

1. Author Correction: Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores (Nature Communications, (2021), 12, 1, (3417), 10.1038/s41467-021-22491-8)

2. S1-Leitlinie: Lumbalpunktion und Liquordiagnostik: Zusammenfassung der Leitlinie der Deutschen Gesellschaft für Neurologie

3. New insights into the genetic etiology of Alzheimer's disease and related dementias

4. S1 guidelines “lumbar puncture and cerebrospinal fluid analysis” (abridged and translated version)

5. Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview

6. New insights into the genetic etiology of Alzheimer's disease and related dementias

7. Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

8. Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

9. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores

10. Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview

16. Association of RDoC dimensions with post-mortem brain transcriptional profiles in Alzheimer's Disease.

17. Plasma amyloid beta X-42/X-40 ratio and cognitive decline in suspected early and preclinical Alzheimer's disease.

18. FTIR Spectroscopy and Blood-Derived Extracellular Vesicles Duo in Alzheimer's Disease.

19. Dimensional clinical phenotyping using post-mortem brain donor medical records: post-mortem RDoC profiling is associated with Alzheimer's disease neuropathology.

20. Bioinformatic analysis of the SPs and NFTs proteomes unravel putative biomarker candidates for Alzheimer's disease.

21. Author Correction: Common variants in Alzheimer's disease and risk stratification by polygenic risk scores.

22. Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers.

23. Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview.

24. Diagnostic performance of automated plasma amyloid-β assays combined with pre-analytical immunoprecipitation.

25. Medium-term and peri-lockdown course of psychosocial burden during the ongoing COVID-19 pandemic: a longitudinal study on patients with pre-existing mental disorders.

26. Identification of risk factors for delirium, cognitive decline, and dementia after cardiac surgery (FINDERI-find delirium risk factors): a study protocol of a prospective observational study.

27. Novel Exosome Biomarker Candidates for Alzheimer's Disease Unravelled Through Mass Spectrometry Analysis.

28. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.

29. Detection and quantification of Aβ-3-40 (APP669-711) in cerebrospinal fluid.

30. Evolution of psychosocial burden and psychiatric symptoms in patients with psychiatric disorders during the Covid-19 pandemic.

32. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores.

33. Autoantibody-associated psychiatric syndromes in children: link to adult psychiatry.

34. Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer's disease.

35. Exosomal Aβ-Binding Proteins Identified by "In Silico" Analysis Represent Putative Blood-Derived Biomarker Candidates for Alzheimer´s Disease.

36. Current clinical practice of electroconvulsive therapy and repetitive transcranial magnetic stimulation in psychiatry, a German sample.

37. Autoantibody-associated psychiatric symptoms and syndromes in adults: A narrative review and proposed diagnostic approach.

38. Development and Technical Validation of an Immunoassay for the Detection of APP 669-711 (Aβ -3-40 ) in Biological Samples.

39. To Be Continued? Long-Term Treatment Effects of Antidepressant Drug Classes and Individual Antidepressants on the Risk of Developing Dementia: A German Case-Control Study.

40. Nuclear medical imaging as part of dementia diagnostics in psychiatric day-care clinics and inpatient care settings.

41. Prevalence of affective disorders and dementia in inflammatory polyarthropathies.

42. Serum neurofilament light chain (NFL) remains unchanged during electroconvulsive therapy.

43. Pre-Analytical Sampling and Storage Conditions of Amyloid-β Peptides in Venous and Capillary Blood.

44. Potential of FTIR Spectroscopy Applied to Exosomes for Alzheimer's Disease Discrimination: A Pilot Study.

45. CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer's disease.

46. [New biomarkers for Alzheimer's disease in cerebrospinal fluid and blood].

47. Claims Data Analysis on the Dispensing of Tricyclic Antidepressants Among Patients With Dementia in Germany.

48. Comparison between amyloid-PET and CSF amyloid-β biomarkers in a clinical cohort with memory deficits.

49. Validation of a prototype tau Thr231 phosphorylation CSF ELISA as a potential biomarker for Alzheimer's disease.

50. Higher Level of Mismatch in APOEε4 Carriers for Amyloid-Beta Peptide Alzheimer's Disease Biomarkers in Cerebrospinal Fluid.

Catalog

Books, media, physical & digital resources